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Abstract 
Human breast cancer represents a group of highly heterogeneous lesions consisting of about 
20 morphologically and immnohistochemically distinct subtypes with substantially different 
prognoses. Our recent studies have suggested that all breast cancer subtypes, however, may 
share a common pathway, tumor cell budding from focally disrupted tumor capsules, for their 
invasion. The potential mechanisms and clinical implications of our observations are discussed.  
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1. Introduction 
Human breast cancer represents a group of 
highly heterogeneous lesions, consisting of about 20 
morphologically distinct subtypes [1,2]. Breast cancers 
also have highly variable molecular and immunohis-
tochemical signatures, and could be roughly divided 
into 5-categories based on expression of estrogen re-
ceptor (ER), progesterone receptor (ER), human epi-
dermal growth factor receptor-1 and 2 (HER-1 and 2), 
and cytokeratins 5/6 [3-5]. The clinical course and 
prognosis of these subtypes differ substantially. In-
flammatory and pregnancy-associated breast cancers 
have the most aggressive clinical course, in which 
many tumors had undergone extensive invasion or 
metastasis at the diagnosis [6-9]. In sharp contrast, 
small tubular and mucinous carcinomas have the 
most indolent clinical course, in which most 
pre-invasive tumors do not progress during patients’ 
lifetime [1,2].  
Despite the substantial differences in the mor-
phology and immunohistochemistry, all breast cancer 
subtypes are likely to share a common pathway for 
invasion due to their common structural features. The 
epithelium of all normal and pre-invasive breast can-
cers is physically separated from the stroma and 
vascular structures by a dense fibrous capsule con-
sisting of the basement membrane and a layer of 
myoepithelial cells (except tubular carcinoma), which 
are permanent structural elements and are largely 
independent of hormonal regulation and biophysio-
logical condition [10-12] (Fig 1). Thus, the disruption 
of the tumor capsule is a pre-requisite for all breast 
cancer subtype derived invasion.  
2. Tumor cell budding from focally disrupted 
tumor capsules  
As the absence of the myoepithelial cell layer is 
one of the most distinct morphological features of 
invasive breast lesions, our recent studies have at-
tempted to elucidate the early alterations of the 
myoepithelial cells and their impact on associated Journal of Cancer 2010, 1 
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epithelial cells during tumor progression. Our studies 
of about 1,000 cases of human breast tumors revealed 
that a subset of pre-invasive tumors harbored focal 
disruptions (the absence of myoepithelial cells re-
sulting in a gap larger than the combined size of at 
least 3-epithelial cells) in the surrounding tumor 
capsules. The frequency of focal disruptions varied 
significantly, from none in a majority of the cases to 
about 1/3 of the pre-invasive tumor nests showing 
focal tumor capsule disruptions in about 15% of the 
cases [13-17].  
Focal disruptions in the tumor capsule appear to 
substantially impact both the morphological and bio-
logical presentations of associated epithelial cells. 
Epithelial cells overlying these focal disruptions were 
generally arranged as tongue- or finger-like projec-
tions. Cells within different projections from the same 
case or different cases were morphologically similar, 
but they often differed substantially in size, shape, 
density, and polarity from adjacent cells within the 
same tumor. These cell projections also displayed the 
following unique features: 
2.1. Morphological signs of stromal invasion 
The size of these cell projections varied from a 
few to over 100 individual cells. Some large cell pro-
jections penetrated deep into the stroma, and cells at 
the tip of projections were often disassociated from 
the tumor core (Fig 2). Focal tumor capsule disrup-
tions with budding cells were seen in all breast cancer 
subtypes with a higher frequency in aggressive and 
lower frequency in indolent lesions. 
2.2. The loss of estrogen receptor (ER) expres-
sion 
 All or nearly all the cells within a vast majority 
(over 86%) of the budding cell projections overlying 
focally disrupted tumor capsules were consistently 
devoid of ER expression, whereas all or nearly all ad-
jacent cells within the same tumors were strongly 
positive for ER (Fig 3).  
2.3. Cytoplasmic expression of HER-2 and 
E-cadherin  
A majority of these cell projections showed sub-
stantially elevated expression of HER-2 and cell sur-
face adhesion molecule E-cadherin [18,19]. The 
sub-cellular localization of both HER-2 and 
E-cadherin, however, was cytoplasmic, rather than 
the typical membrane-association [18,19] (Fig 4).  
2.4. Significantly higher frequency of loss of he-
terozygosity (LOH)  
In 5 selected cases, these budding cell projections 
overlying focally disrupted tumor capsules and adja-
cent counterparts within the same tumor were mi-
crodissected and assessed for LOH. Budding cell 
projections had significantly higher or different LOH 
in 10 of the 15 markers [13] (Fig 5).  
 
 
Fig 1. Structural relations among epithelium (EP), myoepithelium (ME), basement membrane (BM) and stroma (ST). Human 
breast sections were double immunostained for smooth muscle actin (red) and collagen IV (brown). 500X. 
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Fig 2. Focal capsule disruptions with budding tumor cells. Human breast tissue sections were immunostained with a tumor 
capsule maker, sooth muscle actin (SMA) (red). Circles identify budding tumor cells overlying focally disrupted tumor 
capsule. Note that tumor cells at the tips of the projections are often dissociated from the tumor core. 300X. 
 
 
 
 
Fig 3. Loss of ER expression in cell projections overlying focally disrupted tumor capsules. Human breast tissue sections 
from 4 different cases were double immunostained for SMA (red) and ER (brown). Circles identify budding cell projections 
overlying focally disrupted tumor capsules. Note that although these tumors represent morphologically different subtypes, 
all the budding cell projections overlying focally disrupted tumor capsules share a very similar immunohistochemical and 
morphological profile. 100X.  
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Fig 4. Cytoplasmic expression of HER-2 (A-B) and E-cadherin (C-D). Human breast tissue sections from four different cases 
were double immunostained for SMA (red) and E-cadherin or HER-2 (black). Circles identify elevated cytoplasmic ex-
pression of HER-2 and E-cadherin exclusively or preferentially in budding cell projections overlying focally disrupted tumor 
capsules. 
 
 
 
Fig 5. A higher frequency of genetic instabilities in cell projections overlying focally disrupted tumor capsule. A human breast 
tissue section was double immunostained for SMA (red) and ER (brown). Circle identifies microdissected ER negative cell 
projections overlying the focally disrupted tumor capsule. Square identifies ER positive cells within the tumor core. Arrows 
identify LOH.  
 
 
Although tumor cell budding from focally dis-
rupted tumor capsules was seen in all breast cancer 
subtypes, the frequency and size of the capsule dis-
ruptions and the cell projections varied significantly 
among different subtypes. Large focal disruptions 
and large budding cell projections (with about 100 
individual cells) were exclusively or preferentially 
seen in duct-derived and clinically more aggressive 
subtypes. Clinically indolent tubular carcinoma has 
the lowest frequency of tumor capsule disruptions 
with budding tumor cells (not shown).  
3. Potential mechanism(s) of tumor capsule 
disruptions and tumor cell budding 
It is a commonly held belief that the disruption 
or degradation of the tumor capsules is triggered 
primarily, if not solely, by an overproduction of pro-
teolytic enzymes produced by cancer or stromal cells 
[20-22]. This belief, however, is hard to reconcile with 
two main facts. First, although most pre-invasive 
breast cancers show high levels of proteolytic enzyme 
expression, only about 30% of them show the degra-Journal of Cancer 2010, 1 
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dation of the tumor capsules and subsequent invasion 
[23-27]. Second, results from worldwide human clin-
ical trials with a wide variety of proteolytic enzyme 
specific inhibitors to treat or prevent tumor invasion 
have been very disappointing [28,29].  
Based on results from our recent studies [13-19], 
we have proposed that tumor capsule degradation 
and tumor invasion is triggered by focal myoepitheli-
al cell degeneration-induced autoimmunoreactions 
that cause focal disruptions in the tumor capsule, 
which selectively favor monoclonal proliferation of 
tumor stem cells or biologically more aggressive cell 
clones overlying the focal disruptions [30]. The ratio-
nale of our hypothesis is that: since the myoepithelial 
cell layer is the sole source of several tumor suppres-
sors and the epithelium is normally devoid of blood 
vessels and lymphatic ducts, a focal disruption in the 
tumor capsule is likely to have several consequences: 
(1) a localized loss of tumor suppressors and para-
crine inhibitory functions, which confers tumor cell 
growth advantages to escape from the programmed 
cell death [31,32], (2) a localized increasing of per-
meability for nutrients and growth factors, and al-
tered oxygen level, which selectively favors the pro-
liferation of progenitor or stem cells [33,34], (3) a lo-
calized increasing of leukocyte infiltration, which di-
rectly export growth factors to tumor cells through 
direct physical contact [35,36], and (4) the direct tu-
mor-stromal cell contact, which augments the expres-
sion of stromal MMP or represses the expression of 
E-cadherin and other cell surface adhesion molecules, 
which facilitates epithelial-mesenchymal transition 
[37,38]. These alterations could individually or collec-
tively lead to increasing proliferation and motility in 
tumor cells overlying focally disrupted tumor cap-
sules.  
4. Clinical implications of tumor cell budding 
from focally disrupted tumor capsules 
 Together, our findings suggest that tumor cell 
budding from focally disrupted tumor capsules is 
likely to represent a common pathway shared by all 
breast cancer subtypes for their invasion. As the dis-
ruption of the tumor capsule is a pre-requisite for 
tumor invasion, budding cell projections from focally 
disrupted tumor capsules seen in our studies are 
likely to represent the direct precursors of invasive 
lesions. Our findings and speculation are in total 
agreement with those of previous studies of human 
esophageal and colorectal cancers, which have shown 
that tumors with budding cells have a significantly 
more aggressive clinical course and worse prognosis 
[39-41]. Thus, microdissecting these budding cell 
projections for molecular and biochemical analyses 
could potentially lead to the identification of the spe-
cific trigger factors for tumor invasion. The develop-
ment of a quantitative immunohistochemical assay to 
measure the frequency and extent of tumor capsule 
disruptions with budding cells may significantly faci-
litate early detection of pending invasive tumors or 
patients at greater risk to develop invasive tumors. 
The development of therapeutic agents to specifically 
target these budding tumor cell projections could po-
tentially provide the most effective regimen for early 
intervention and prevention of breast cancer invasion. 
However, it is currently very difficult, if not impossi-
ble, to fully elucidate the molecular and biochemical 
profiles of these very limited budding cells, due to the 
lack of sensitive technical approaches.  
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